Categories: News

Coloplast A/S – Q1 2023/24 Earnings Release – Invitation for conference call on 9 February 2024 at 11.00am CET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Friday, 9 February 2024 at 11.00 – 12.00 CET
In connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.
The webcast of the conference call will be available during and after the event.

Coloplast will be represented by:
Kristian Villumsen – President & CEO
Anders Lonning-Skovgaard  Executive Vice President, CFO
Aleksandra Dimovska – Senior Director, Investor Relations
Kristine Husted Munk – Senior Manager, Investor Relations

Webcast
For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:
Access the webcast here


Dial-in details
To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.
Register for the conference call here

 

For more information, please contact:

Aleksandra Dimovska – Senior Director, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 2458. E-mail: dkadim@coloplast.com

Kristine Husted Munk – Senior Manager, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 3266. E-mail: dkkhu@coloplast.com

Hannah K. Larsen – Coordinator & PA, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 3616. E-mail: dkhakl@coloplast.com

 

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment

Staff

Recent Posts

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone…

19 minutes ago

AI-Driven Personalized Nutrition and Wellness Solutions Market worth USD 17,867.16 MN by 2032 | Credence Research

LONDON, Dec. 4, 2025 /PRNewswire/ -- The global AI-Driven Personalized Nutrition and Wellness Solutions Market…

3 hours ago

Shinoda Dental Signs MOU with Global Milling Manufacturer, Expands CAD/CAM Portfolio with Leading Brands

With expanded access to brands like Planmeca, Roland, Dentsply Sirona, and Ivoclar, Shinoda Dental becomes…

3 hours ago

BLACK PASTORS UNITED FOR EDUCATION (BPUE) WINS THE 2025 GREGOR G. PETERSON PRIZE IN VENTURE PHILANTHROPY

HARRISBURG, Pa., Dec. 3, 2025 /PRNewswire/ -- Black Pastors United for Education (BPUE), a faith-based…

9 hours ago

Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic…

9 hours ago

ASPN Pharmacies Achieves Surescripts® RxTransfer Certification

FLORHAM PARK, N.J., Dec. 3, 2025 /PRNewswire/ -- ASPN Pharmacies, a leading patient services hub…

9 hours ago